Follow-up cohort of patients with chronic obstructive pulmonary disease treated by Seretide Diskus 500 µg / 50 doses ® FRESH-PEF164-en Céline PRIBIL Follow-up cohort of patients with chronic obstructive pulmonary disease treated by Seretide Diskus 500 µg / 50 doses ® USB FRESH-PEF164-en 164 FRESH-PEF164 Céline PRIBIL GLAXOSMITHKLINE (FRANCE) Epidemiology France Portal (PEF) GLAXOSMITHKLINE (FRANCE) null Céline;PRIBIL cohort Seretide Diskus Pulmonary medicine Healthcare system determinants: Use of care Healthcare system determinants Describe the population pursuing SERETIDE Diskus 500 µg / 50 doses within the framework of treating OCPD, the methods for prescribing it and their actual conditions of use (observance in particular) as well as the clinical change in patients. Evaluate the impact of the fixed-dose combinations on objective morbidity and on perceived morbidity of OCPD. null France Individuals Patients population Male Female Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) • Patient in whom a treatment via Seretide® Diskus 50 µg / 50 doses is initiated on the day of inclusion • Patients over the age of 40 years, • Smokers or ex-smokers (> 15 pack-years) Clinical data Participant-reported health data Health event/morbidity Health care consumption and services Quality of life/health perception Other Through independent healthcare practitioners [500-1000[ individuals Self-administered questionnaire Interview with the participant (including clinical) Observational Study Observational Study 767 Unknown Restricted access Access on specific project only